Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation

被引：46
|
作者：
Chang, H
Qi, XY
Samiee, S
Yi, QL
Chen, C
Trudel, S
Mikhael, J
Reece, D
Stewart, AK
机构：
[1] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Dept Lab Hematol, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada
[3] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M5G 2M9, Canada
[4] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Dept Biostat, Toronto, ON M5G 2M9, Canada
来源：
BONE MARROW TRANSPLANTATION | 2005年 / 36卷 / 09期
基金：
加拿大健康研究院;
关键词：
multiple myeloma; IgH translocations; 13q deletions; p53; deletions; fluorescence in situ hybridization; autologous stem cell transplantation;
D O I：
10.1038/sj.bmt.1705131
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
Genetic aberrations have emerged as major prognostic factors for patients with multiple myeloma ( MM). We evaluated 126 MM patients for t(4; 14) or t(11; 14), 13q or p53 deletions and correlated the number of genetic aberrations with patient's clinical outcome following undergoing autologous stem cell transplantation. W e demonstrate the significance of genetic-based risk classification that clearly segregate patients into low ( no genetic abnormalities or only t( 11; 14)), intermediate ( any one of the genetic abnormalities other than t( 11; 14)) and high-risk groups ( any two or more of the genetic abnormalities other than t( 11; 14)). High-risk patients do not bene. t from stem cell transplant and should be offered alternative therapies.
引用
收藏
页码：793 / 796
页数：4
相关论文
共 50 条
  • [21] Autologous stem cell transplantation in multiple myeloma patients with renal impairment
    Zhai, Yingying
    Yan, Lingzhi
    Jin, Song
    Yan, Shuang
    Yao, Weiqin
    Shang, Jingjing
    Shi, Xiaolan
    Wang, Ruju
    Kang, Huizhu
    Lu, Jing
    Zhu, Ziling
    Tang, Fang
    Wei, Feng
    Fu, Chengcheng
    Wu, Depei
    ANNALS OF HEMATOLOGY, 2023, 102 (03) : 621 - 628
  • [22] Autologous stem cell transplantation in multiple myeloma patients with renal impairment
    Yingying Zhai
    Lingzhi Yan
    Song Jin
    Shuang Yan
    Weiqin Yao
    Jingjing Shang
    Xiaolan Shi
    Ruju Wang
    Huizhu Kang
    Jing Lu
    Ziling Zhu
    Fang Tang
    Feng Wei
    Chengcheng Fu
    Depei Wu
    Annals of Hematology, 2023, 102 : 621 - 628
  • [23] Experience in Autologous Stem Cell Transplantation in Elderly Multiple Myeloma Patients
    Seehaus, Cristian
    Brulc, Erika
    Schutz, Natalia
    Basquiera, Ana
    Fantl, Dorotea
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S245 - S245
  • [24] Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation
    Satoshi Yamasaki
    Goichi Yoshimoto
    Kentaro Kohno
    Hideho Henzan
    Takatoshi Aoki
    Kazuki Tanimoto
    Yasuhiro Sugio
    Tsuyoshi Muta
    Tomohiko Kamimura
    Yuju Ohno
    Ryosuke Ogawa
    Tetsuya Eto
    Koji Nagafuji
    Toshihiro Miyamoto
    Koichi Akashi
    Hiromi Iwasaki
    International Journal of Hematology, 2019, 109 : 98 - 106
  • [25] Superior Survival in African American Patients Who Underwent Autologous Stem Cell Transplantation for Multiple Myeloma
    Sweiss, Karen
    Oh, Annie
    Calip, Gregory S.
    Rondelli, Damiano
    Patel, Pritesh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (08): : E506 - E511
  • [26] Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma
    Pasvolsky, Oren
    Ghanem, Sassine
    Milton, Denai R.
    Masood, Adeel
    Tanner, Mark R.
    Bashir, Qaiser
    Srour, Samer
    Saini, Neeraj
    Lin, Paul
    Ramdial, Jeremy
    Nieto, Yago
    Lee, Hans C.
    Patel, Krina K.
    Kebriaei, Partow
    Thomas, Sheeba K.
    Weber, Donna M.
    Orlowski, Robert Z.
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (12): : 757 - 762
  • [27] Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation
    Yamasaki, Satoshi
    Yoshimoto, Goichi
    Kohno, Kentaro
    Henzan, Hideho
    Aoki, Takatoshi
    Tanimoto, Kazuki
    Sugio, Yasuhiro
    Muta, Tsuyoshi
    Kamimura, Tomohiko
    Ohno, Yuju
    Ogawa, Ryosuke
    Eto, Tetsuya
    Nagafuji, Koji
    Miyamoto, Toshihiro
    Akashi, Koichi
    Iwasaki, Hiromi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (01) : 98 - 106
  • [28] A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
    Guo, Wancheng
    Strouse, Christopher
    Mery, David
    Siegel, Eric R.
    Munshi, Manit N.
    Ashby, Timothy Cody
    Cheng, Yan
    Sun, Fumou
    Wanchai, Visanu
    Zhang, Zijun
    Bailey, Clyde
    Alapat, Daisy V.
    Peng, Hongling
    Al Hadidi, Samer
    Thanendrarajan, Sharmilan
    Schinke, Carolina
    Zangari, Maurizio
    van Rhee, Frits
    Tricot, Guido
    Shaughnessy Jr, John D.
    Zhan, Fenghuang
    CANCERS, 2024, 16 (06)
  • [29] Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation
    Geng, Chuanying
    Zhou, Huixing
    Wang, Huijuan
    Li, Yanchen
    Leng, Yun
    Zhang, Zhiyao
    Jian, Yuan
    Yang, Guangzhong
    Chen, Wenming
    BMC CANCER, 2022, 22 (01)
  • [30] Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation
    Chuanying Geng
    Huixing Zhou
    Huijuan Wang
    Yanchen Li
    Yun Leng
    Zhiyao Zhang
    Yuan Jian
    Guangzhong Yang
    Wenming Chen
    BMC Cancer, 22
12345